Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Stig Linder, Maria Hägg Olofsson, Richard Herrmann & Engin Ulukaya. (2010) Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Review of Molecular Diagnostics 10:3, pages 353-359.
Read now
Read now
Articles from other publishers (51)
Maria Efthymia Katsa, Eirini Kostopoulou, Tzortzis Nomikos, Anastasios Ioannidis, Vasileios Sarris, Spyridon Papadogiannis, Bessie E. Spiliotis & Andrea Paola Rojas Gil. (2023) The Response of Antioxidant Enzymes and Antiapoptotic Markers to an Oral Glucose Tolerance Test (OGTT) in Children and Adolescents with Excess Body Weight. International Journal of Molecular Sciences 24:22, pages 16517.
Crossref
Crossref
Tareq Saleh, Sarah Bloukh, Mira Hasan & Sofian Al Shboul. (2023) Therapy-induced senescence as a component of tumor biology: Evidence from clinical cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:6, pages 188994.
Crossref
Crossref
Sofian Al Shboul, Mohammed El-Sadoni, Ahmad Alhesa, Nisreen Abu Shahin, Dua Abuquteish, Ola Abu Al Karsaneh, Elham Alsharaiah, Mohammad A. Ismail, Liliya Tyutyunyk-Massey, Moureq R. Alotaibi, Victoria Neely, Hisashi Harada & Tareq Saleh. (2023) NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy. Scientific Reports 13:1.
Crossref
Crossref
Dilara ÜLGER ÖZBEK, Savaş KARAKUŞ & Sevtap BAKIR. (2023) Levels of oxidative stress and apoptosis-related biomarkers in endometriosisEndometrioziste oksidatif stres ve apoptozla ilişkili biyobelirteçlerin düzeyleri. Cukurova Medical Journal 48:2, pages 480-488.
Crossref
Crossref
Merin Babu & Keechilat Pavithran. (2022) Therapeutic Drug Monitoring as a Tool for Therapy Optimization. Drug Metabolism and Bioanalysis Letters 15:2, pages 93-100.
Crossref
Crossref
Helena J Janse van Rensburg, Pavlina Spiliopoulou & Lillian L Siu. (2022) Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents. The Oncologist 27:5, pages 352-362.
Crossref
Crossref
H. Mehmet Turk, Altay Aliyev, Rabia Sevda Celik, Mesut Seker, Ezgi Coban, Tarık Demir, Tuba Baydas & Abdurrahim Kocyigit. (2020) Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer. Current Problems in Cancer 44:1, pages 100497.
Crossref
Crossref
Gareth J. VealEdward B. AmankwatiaMarie-Noëlle PaludettoTill MöcklinghoffFiona ThomsonNicolas André, Joseph CiccoliniEtienne Chatelut. (2019) Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. Therapeutic Drug Monitoring 41:2, pages 142-159.
Crossref
Crossref
Tihamer Molnar, Kata Borocz, Timea Berki, Laszlo Szapary, Alex Szolics, Jozsef Janszky, Zsolt Illes & Peter Csecsei. (2019) Subacute Elevation of Plasma Level of Caspase-Cleaved Cytokeratin-18 is Associated with Hemorrhagic Transformation and Functional Outcome in Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases 28:3, pages 719-727.
Crossref
Crossref
Jiangling Yang, Sicheng Gao, Jian Xu & Junfeng Zhu. (2018) Prognostic value and clinicopathological significance of serum- and tissue-based cytokeratin 18 express level in breast cancer: a meta-analysis. Bioscience Reports 38:2.
Crossref
Crossref
Kayla F. Goliwas, Jillian R. Richter, Hawley C. Pruitt, Lita M. Araysi, Nicholas R. Anderson, Rajeev S. Samant, Susan M. Lobo-Ruppert, Joel L. Berry & Andra R. Frost. (2017) Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a Tissue Engineered Breast Cancer Model. Scientific Reports 7:1.
Crossref
Crossref
Mark N. Stein, Joseph R. Bertino, Howard L. Kaufman, Tina Mayer, Rebecca Moss, Ann Silk, Nancy Chan, Jyoti Malhotra, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Bruce G. Haffty, Robert S. DiPaola, Tracie Saunders, Andrew Zloza, Sherri Damare, Yasmeen Beckett, Bangning Yu, Saltanat Najmi, Christian Gabel, Siobhan Dickerson, Ling Zheng, Wafik S. El-Deiry, Joshua E. Allen, Martin Stogniew, Wolfgang Oster & Janice M. Mehnert. (2017) First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clinical Cancer Research 23:15, pages 4163-4169.
Crossref
Crossref
Rahul Khanna. (2016) Expression of Cytokeratin - 18 in Serum as a Biomarker of Apoptosis & Necrosis in Carcinoma Breast. Journal of Cancer Prevention & Current Research 5:2.
Crossref
Crossref
Zahra Malek-Hosseini, Abdolaziz Khezri & Zahra Amirghofran. (2016) Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression. Iranian Journal of Cancer Prevention In Press:In Press.
Crossref
Crossref
BO YIN, MO ZHANG, YU ZENG, YOUQIANG LI, CHAO ZHANG & YONGSHENG SONG. (2016) Downregulation of cytokeratin 18 is associated with paclitaxel-resistance and tumor aggressiveness in prostate cancer. International Journal of Oncology 48:4, pages 1730-1736.
Crossref
Crossref
Shui-Jun Gu, Ming Lu, Hong-Fei Xuan, Xin-Zhi Chen, Wei-Feng Dong, Xiao-Feng Yan, Yun Si, Guo-Liang Gao, Dian-Xiang Hu & Jian-Qing Miao. (2016) Predictive value of serum caspase-cleaved cytokeratin-18 concentrations after acute intracerebral hemorrhage. Clinica Chimica Acta 452, pages 124-128.
Crossref
Crossref
Buse Cevatemre, Engin Ulukaya, Mehmet Sarimahmut, Arzu Yilmaztepe Oral & Fiona M. Frame. (2015) The M30 assay does not detect apoptosis in epithelial-derived cancer cells expressing low levels of cytokeratin 18. Tumor Biology 36:9, pages 6857-6865.
Crossref
Crossref
Fatma Sen, Ibrahim Yildiz, Hatice Odabas, Makbule Tambas, Leyla Kilic, Ahmet Karadeniz, Musa Altun, Meltem Ekenel, Murat Serilmez, Derya Duranyildiz, Sevil Bavbek & Mert Basaran. (2014) Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma. Tumor Biology 36:2, pages 1039-1044.
Crossref
Crossref
Patuma Sinthujaroen, Nattaporn Wanachottrakul, Decha Pinkaew, John R. Petersen, Amornrat Phongdara, Melinda Sheffield-Moore & Ken Fujise. (2014) Elevation of serum fortilin levels is specific for apoptosis and signifies cell death in vivo. BBA Clinical 2, pages 103-111.
Crossref
Crossref
Faruk Tas, Senem Karabulut, Ibrahim Yildiz & Derya Duranyildiz. (2014) Clinical significance of serum M30 and M65 levels in patients with breast cancer. Biomedicine & Pharmacotherapy 68:8, pages 1135-1140.
Crossref
Crossref
Sunil Sharma, Elisabeth G. de Vries, Jeffrey R. Infante, Corina N. Oldenhuis, Jourik A. Gietema, Lin Yang, Sanela Bilic, Katie Parker, Michael Goldbrunner, Jeffrey W. Scott & Howard A. BurrisIIIIII. (2013) Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs 32:1, pages 135-144.
Crossref
Crossref
Faruk Tas, Senem Karabulut, Elif Bilgin, Fatma Sen, Ibrahim Yildiz, Didem Tastekin, Rumeysa Ciftci & Derya Duranyildiz. (2013) Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. Tumor Biology 34:6, pages 3529-3536.
Crossref
Crossref
Katsunobu Oyama, Sachio Fushida, Jun Kinoshita, Koichi Okamoto, Isamu Makino, Keishi Nakamura, Hironori Hayashi, Masafumi Inokuchi, Hisatoshi Nakagawara, Hidehiro Tajima, Hideto Fujita, Hiroyuki Takamura, Itasu Ninomiya, Hirohisa Kitagawa, Takashi Fujimura & Tetsuo Ohta. (2012) Serum cytokeratin 18 as a biomarker for gastric cancer. Clinical and Experimental Medicine 13:4, pages 289-295.
Crossref
Crossref
Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Serkan Keskin, Derya Duranyildiz, Elif Bilgin, Rian Disci, Meltem Ekenel, Emin Darendeliler, Sevil Bavbek & Mert Basaran. (2013) Serum M65 as a Biomarker for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 11:3, pages 290-296.
Crossref
Crossref
Ibrahim Yildiz, Faruk Tas, Leyla Kilic, Fatma Sen, Pinar Saip, Yesim Eralp, Serkan Keskin, Senem Karabulut, Rumeysa Ciftci, Murat Serilmez, Vildan Yasasever & Adnan Aydiner. (2013) A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer. Cancer Chemotherapy and Pharmacology 72:2, pages 437-444.
Crossref
Crossref
Bala Basak Oven Ustaalioglu, Ahmet Bilici, Serif Ercan, Mesut Seker, Asuman Orcun & Mahmut Gumus. (2013) The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer. Medical Oncology 30:2.
Crossref
Crossref
Hiroyuki Sumi, Masato Yabuki, Kenichi Iwai, Megumi Morimoto, Ryosuke Hibino, Masakazu Inazuka, Kentaro Hashimoto, Yohei Kosugi, Kazunobu Aoyama, Shunsuke Yamamoto, Mie Yoshimatsu, Hideki Yamasaki, Ryuichi Tozawa, Tomoyasu Ishikawa & Sei Yoshida. (2013) Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins. Molecular Cancer Therapeutics 12:2, pages 230-240.
Crossref
Crossref
Amanda F. Baker, Denise J. Roe, Cynthia Laughren, Janice L. Cohen, Heather M. Wright, Mary C. Clouser, Haiyan Cui, David S. Alberts & Setsuko K. Chambers. (2012) Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer. Investigational New Drugs 31:1, pages 160-166.
Crossref
Crossref
Tian-Qing Chu, Hao Ding, David H. Garfield, Ai-Qin Gu, Jun Pei, Wei-Dong Du & Bao-Hui Han. (2012) Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Endostatin and Paclitaxel–Carboplatin Chemotherapy? A Retrospective Study. Journal of Thoracic Oncology 7:12, pages 1781-1789.
Crossref
Crossref
Ahmet Bilici, Bala Basak Oven Ustaalioglu, Serif Ercan, Mesut Seker, Burcak Erkol Yilmaz, Asuman Orcun & Mahmut Gumus. (2012) The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer. Tumor Biology 33:6, pages 2201-2208.
Crossref
Crossref
Sharon Leong, Andrea C. Nunez, Mike Z. Lin, Ben Crossett, Richard I. Christopherson & Robert C. Baxter. (2012) iTRAQ-Based Proteomic Profiling of Breast Cancer Cell Response to Doxorubicin and TRAIL. Journal of Proteome Research 11:7, pages 3561-3572.
Crossref
Crossref
Yu-Rong Weng, Yun Cui & Jing-Yuan Fang. (2012) Biological Functions of Cytokeratin 18 in Cancer. Molecular Cancer Research 10:4, pages 485-493.
Crossref
Crossref
Ahmet Bilici, Bala Basak Oven Ustaalioglu, Serif Ercan, Asuman Orcun, Mesut Seker, Taflan Salepci & Mahmut Gumus. (2010) Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?. Cancer Chemotherapy and Pharmacology 68:2, pages 309-316.
Crossref
Crossref
Engin Ulukaya, Ceyda Acilan & Yusuf Yilmaz. (2011) Apoptosis: why and how does it occur in biology?. Cell Biochemistry and Function 29:6, pages 468-480.
Crossref
Crossref
Jeffrey Cummings, Cong Zhou & Caroline Dive. (2011) Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays. Journal of Chromatography B 879:13-14, pages 887-893.
Crossref
Crossref
Engin Ulukaya, Esra Karaagac, Ferda Ari, Arzu Oral, Saduman Adim, Asuman Tokullugil & Türkkan Evrensel. (2011) Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients. Radiology and Oncology 45:2.
Crossref
Crossref
Lian Zhang, Brian D. Kavanagh, Andrew M. Thorburn & D. Ross Camidge. (2010) Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli. Clinical Cancer Research 16:17, pages 4478-4489.
Crossref
Crossref
Emel Yaman, Ugur Coskun, Banu Sancak, Suleyman Buyukberber, Banu Ozturk & Mustafa Benekli. (2010) Serum M30 levels are associated with survival in advanced gastric carcinoma patients. International Immunopharmacology 10:7, pages 719-722.
Crossref
Crossref
Sang Ho ParkHyun Sung KwackKi Sung RyuYoung LeeKu Taek Han. (2010) Measurement of apoptosis using M30 in culture media of cell lines treated with anti-cancer agents. Korean Journal of Obstetrics and Gynecology 53:5, pages 401.
Crossref
Crossref
Banu Ozturk, Ugur Coskun, Banu Sancak, Emel Yaman, Suleyman Buyukberber & Mustafa Benekli. (2009) Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. International Immunopharmacology 9:5, pages 645-648.
Crossref
Crossref
Stig LinderAyodele Alaiya. (2009) Serum efficacy biomarkers for oncology. Biomarkers in Medicine 3:1, pages 47-54.
Crossref
Crossref
Dimitra Micha, Jeff Cummings, Alex Shoemaker, Steven Elmore, Kelly Foster, Martin Greaves, Tim Ward, Saul Rosenberg, Caroline Dive & Kathryn Simpson. (2008) Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer. Clinical Cancer Research 14:22, pages 7304-7310.
Crossref
Crossref
Esther C. de Haas, Alessandra di Pietro, Kathryn L. Simpson, Coby Meijer, Albert J.H. Suurmeijer, Lee J. Lancashire, J. Cummings, Steven de Jong, Elisabeth G.E. de Vries, Caroline Dive & Jourik A. Gietema. (2008) Clinical Evaluation of M30 and M65 ELISA Cell Death Assays as Circulating Biomarkers in a Drug-Sensitive Tumor, Testicular Cancer. Neoplasia 10:10, pages 1041-1048.
Crossref
Crossref
Ying Wang, Qing-Yu He, Sai-Wah Tsao, Yim-Hing Cheung, Anita Wong & Jen-Fu Chiu. (2008) Cytokeratin 8 silencing in human nasopharyngeal carcinoma cells leads to cisplatin sensitization. Cancer Letters 265:2, pages 188-196.
Crossref
Crossref
Jeffrey Cummings, Cassandra Hodgkinson, Rajesh Odedra, Patrizia Sini, Simon P. Heaton, Kirsten E. Mundt, Tim H. Ward, Robert W. Wilkinson, Jim Growcott, Andrew Hughes & Caroline Dive. (2008) Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Molecular Cancer Therapeutics 7:3, pages 455-463.
Crossref
Crossref
J Cummings, T H Ward, A Greystoke, M Ranson & C Dive. (2008) Biomarker method validation in anticancer drug development. British Journal of Pharmacology 153:4, pages 646-656.
Crossref
Crossref
Alastair Greystoke, Andrew Hughes, Malcolm Ranson, Caroline Dive, Jeff Cummings & Tim Ward. (2007) Serum biomarkers of apoptosis. European Journal of Cancer Supplements 5:5, pages 115-127.
Crossref
Crossref
Maria Hägg Olofsson, Takayuki Ueno, Yang Pan, Ren Xu, Feng Cai, Heiko van der Kuip, Thomas E. Muerdter, Maike Sonnenberg, Walter E. Aulitzky, Stephan Schwarz, Elina Andersson, Maria C. Shoshan, Aleksandra Mandic Havelka, Masakazu Toi & Stig Linder. (2007) Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy. Clinical Cancer Research 13:11, pages 3198-3206.
Crossref
Crossref
Normand Marceau, Bert Schutte, Stéphane Gilbert, Anne Loranger, Mieke E.R. Henfling, Jos L.V. Broers, Jasmin Mathew & Frans C.S. Ramaekers. (2007) Dual roles of intermediate filaments in apoptosis. Experimental Cell Research 313:10, pages 2265-2281.
Crossref
Crossref
Engin Ulukaya, Arzu Yilmaztepe, Semra Akgoz, Stig Linder & Mehmet Karadag. (2007) The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56:3, pages 399-404.
Crossref
Crossref
Stig Linder. (2007) Cytokeratin Markers Come of Age. Tumor Biology 28:4, pages 189-195.
Crossref
Crossref